DEA Proposes Schedule I Placement for Psychedelics as FDA Advances Therapy Pathway

DEA Proposes Schedule I Placement for Psychedelic Compounds

The Drug Enforcement Administration published a notice of proposed rulemaking in the Federal Register to classify multiple psychedelic substances as Schedule I controlled substances under 21 U.S.C. § 812. The proposed rule would impose the strictest federal controls on the compounds, defining them as having no currently accepted medical use and a high potential for abuse. The DEA action follows standard administrative procedure under the Controlled Substances Act but arrives amid growing clinical evidence for psychedelic-assisted therapies.

Schedule I placement blocks commercial distribution. It limits research access. It triggers criminal penalties for unauthorized possession or manufacture. The classification puts the targeted compounds in the same category as heroin and LSD.

FDA Advances Accelerated Approval Framework for Psychedelic Therapies

The Food and Drug Administration held a public hearing at its headquarters on September 16, 2026, to discuss regulatory pathways for psychedelic drug development. The agency signaled intent to create an expedited review track for psychedelic-assisted therapies targeting treatment-resistant depression and post-traumatic stress disorder. FDA officials outlined modifications to existing clinical trial endpoints and proposed surrogate markers that could support accelerated approval.

Researchers, patient advocates, and pharmaceutical sponsors currently conducting Phase 2 and Phase 3 trials testified at the hearing. FDA's Center for Drug Evaluation and Research indicated it would issue draft guidance on psychedelic trial design by the end of 2026.

Regulatory Conflict Creates Development Uncertainty

The simultaneous DEA scheduling action and FDA pathway development create conflicting signals for psychedelic drug sponsors and researchers. Companies conducting FDA-authorized clinical trials operate under DEA research registrations that permit controlled handling of Schedule I substances. A final DEA rule tightening controls could increase compliance costs and slow enrollment timelines, even for FDA-sanctioned studies.

Industry observers note the agencies operate under separate statutory mandates. DEA enforces the Controlled Substances Act while FDA regulates drug safety and efficacy under the Federal Food, Drug, and Cosmetic Act. The split isn't unprecedented, but the timing amplifies uncertainty for sponsors with active investigational new drug applications.

Public Comment Period Opens on DEA Proposal

The DEA notice of proposed rulemaking opens a 60-day public comment period, standard for administrative rulemaking under the Administrative Procedure Act. Stakeholders including medical associations, research institutions, and patient advocacy groups are expected to file comments opposing Schedule I placement. The comment window closes in late November 2026, after which DEA will review submissions and publish a final rule or withdraw the proposal.

DEA hasn't disclosed which specific psychedelic compounds are targeted in the proposed rule. The agency typically schedules novel synthetic analogs or compounds flagged by international treaty obligations.

Clinical Trial Pipeline Continues Despite Scheduling Risk

At least seven psychedelic drug candidates are currently in Phase 2 or Phase 3 trials under FDA oversight, targeting indications including major depressive disorder and PTSD. Sponsors hold DEA Schedule I research registrations that permit investigational use. A final DEA rule wouldn't halt ongoing trials but could impose additional security, recordkeeping, and inspection requirements that increase operational costs.

Trial sponsors haven't publicly commented on the DEA proposal. Most companies operate under confidentiality agreements with FDA and avoid public statements on scheduling matters during active development.

What Happens Next

The DEA comment period runs through late November 2026. FDA is expected to release draft guidance on psychedelic trial design by year-end. For full background on federal psychedelic scheduling and policy developments, see the CannIntel topic hub on Psychedelics Federal Scheduling. The next signal: whether FDA sponsors file formal comments opposing the DEA proposal before the November deadline.